Rosiglitazone
Code | Size | Price |
---|
TAR-T0334-25mg | 25mg | £99.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T0334-50mg | 50mg | £111.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T0334-1mL | 1 mL * 10 mM (in DMSO) | £115.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T0334-100mg | 100mg | £136.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T0334-200mg | 200mg | £189.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Rosiglitazone is an insulin sensitizing agent and thiazolidinedione that is indicated for the treatment of type 2 diabetes. Rosiglitazone has been linked to rare instances of acute liver injury.
CAS:
122320-73-4
Formula:
C18H19N3O3S
Molecular Weight:
357.43
Pathway:
Membrane transporter/Ion channel; Metabolism; DNA Damage/DNA Repair; Apoptosis; Autophagy; Cell Cycle/Checkpoint
Purity:
0.9987
SMILES:
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1
Target:
Ferroptosis; TRP/TRPV Channel; PPAR; Autophagy
References
1. Fryer LG, et al. J Biol Chem, 2002, 277(28), 25226-25232.
2. Rzonca SO, et al. Endocrinology, 2004, 45(1), 401-406.
3. Motoshima H, et al. J Clin Endocrinol Metab, 2002, 87(12), 5662-5667.
4. Wilson-Fritch L, et al. J Clin Invest, 2004, 114(9), 1281-1289.
6. Ateyya H, et al. Beneficial effects of rosiglitazone and losartan combination in diabetic rats. Can J Physiol Pharmacol. 2018 Mar;96(3):215-220.
7. Qiu Y, Sun Y, Xu D, et al. Screening of FDA-approved drugs identifies sutent as a modulator of UCP1 expression in brown adipose tissue[J]. EBioMedicine. 2018, 37: 344-355.
8. Zeng X, Zhu S, Lu W, et al. Target identification among known drugs by deep learning from heterogeneous networks[J]. Chemical Science. 2020, 11(7): 1775-1797.